Department of Hematology, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, People's Republic of China.
Department of Laboratory Medicine, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, People's Republic of China.
Hematology. 2024 Dec;29(1):2399375. doi: 10.1080/16078454.2024.2399375. Epub 2024 Sep 9.
Pernicious anemia (PA) is believed to be highly prevalent in Western countries but has rarely been reported in China. The study explores whether PA, an autoimmune disease, is an uncommon cause of cobalamin (vitamin B12) deficiency anemia in China.
Clinical and hematological data were collected from 90 cobalamin deficiency-caused megaloblastic anemia (MA) patients between July 2014 and December 2021. Through anti-intrinsic factor antibody (IFA) and anti-parietal cell antibody (PCA) testing, PA was distinguished from other causes of cobalamin deficiency leading to MA. Meanwhile, 30 healthy controls (HCs) were included to estimate the positive rates of IFA and PCA.
Of the 30 HCs, only one tested positive for IFA, and all 30 tested negative for PCA. Among the 90 patients with cobalamin deficiency-caused MA, 76.7% were positive for IFA, and 47.8% were positive for PCA; a total of 76 patients (84.4%) were diagnosed with PA. The mean follow-up time was 41.0 ± 16.3 months. During the follow-up period, no case relapsed among the continuous cobalamin-supply treatment patients, while 24.4% of patients relapsed due to the interruption of maintenance cobalamin-supplement therapy (the median recurrence time was 54.0 ± 17.7 months).
The proportion of PA in cobalamin deficiency-caused MA patients in Hainan province was higher than 80%, which was more common than expected. Therefore, screening for IFA, PCA, endoscopic biopsy, and thyroid-related parameters are recommended for all cobalamin deficiency-caused MA patients. Furthermore, maintenance cobalamin-supplement therapy is important for PA patients.
据信,恶性贫血(PA)在西方国家高发,但在中国鲜有报道。本研究旨在探讨自身免疫性疾病 PA 是否是中国钴胺素(维生素 B12)缺乏性巨幼细胞贫血(MA)的少见病因。
收集 2014 年 7 月至 2021 年 12 月间 90 例因钴胺素缺乏导致的巨幼细胞性贫血(MA)患者的临床和血液学资料。通过抗内因子抗体(IFA)和抗壁细胞抗体(PCA)检测,将 PA 与其他导致 MA 的钴胺素缺乏病因区分开来。同时,纳入 30 例健康对照(HCs)以评估 IFA 和 PCA 的阳性率。
30 例 HCs 中,仅 1 例 IFA 阳性,所有 HCs 均 PCA 阴性。90 例因钴胺素缺乏导致的 MA 患者中,76.7%的患者 IFA 阳性,47.8%的患者 PCA 阳性;共有 76 例(84.4%)患者诊断为 PA。平均随访时间为 41.0±16.3 个月。在随访期间,持续补充钴胺素的患者无复发,而中断维持性钴胺素补充治疗的患者中有 24.4%复发(中位复发时间为 54.0±17.7 个月)。
海南省因钴胺素缺乏导致的 MA 患者中 PA 的比例高于 80%,高于预期。因此,建议对所有因钴胺素缺乏导致的 MA 患者进行 IFA、PCA、内镜活检和甲状腺相关参数筛查。此外,维持性钴胺素补充治疗对 PA 患者很重要。